Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1628 1655 1699
This examiner grants 39% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17639311 | CO-POTENTIATORS FOR THERAPY OF CYSTIC FIBROSIS CAUSED BY MINIMAL FUNCTION CFTR MUTANTS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17761433 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | Final Rejection | Merck Sharp & Dohme LLC |
| 18447548 | COMPOSITIONS AND METHODS FOR DIGESTIVE HEALTH IN AN CANINE | Non-Final OA | Société des Produits Nestlé S.A. |
| 18415255 | USES OF HNF4 ALPHA AGONISTS | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 18701885 | 2-FLUORODESCHLOROKETAMINE FOR TREATMENT OF DEPRESSION, INCLUDING TREATMENT-RESISTANT DEPRESSION | Non-Final OA | CLEARMIND LABS CORP. |
| 18546831 | COMPOSITION FOR SKIN REGENERATION, WHITENING, ANTIOXIDATION, OR WOUND TREATMENT, COMPRISING STEM CELL-DERIVED EXOSOME AS ACTIVE INGREDIENT, AND USE THEREOF | Non-Final OA | EHLBIO Co., Ltd. |
| 18434887 | Method for the purification from pyrrolizidine alkaloids of biologically active plant products containing furostanol saponins and a biologically active plant product derived from Tribulus terrestris | Non-Final OA | VEMO-99 OOD |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | Non-Final OA | LDN Pharma Limited |
| 18573049 | BLOOD FLOW INCREASING AGENT FOR DORSOLATERAL PREFRONTAL CORTEX, DORSOLATERAL PREFRONTAL CORTEX ACTIVATOR, FOOD FOR INCREASING BLOOD FLOW IN DORSOLATERAL PREFRONTAL CORTEX, AND FOOD FOR ACTIVATING DORSOLATERAL PREFRONTAL CORTEX | Non-Final OA | KINJIRUSHI CO., LTD. |
| 18510944 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | Non-Final OA | VivaVision Biotech, Inc |
| 18387913 | PPARG INVERSE AGONISTS AND USES THEREOF | Non-Final OA | Flare Therapeutics Inc. |
| 18041682 | POLYMORPHS OF 5-BROMO-6-CHLORO-3-INDOXYL CAPRYLATE | Final Rejection | Biosynth AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy